Sunday, June 10

SCIENCE-IN-PROGRESS

08.00-09.15 hours, Room: Léhar I+II

THE ORIGIN AND FATE OF HEMOPOIETIC STEM CELLS

Chair: A. Green (Cambridge Institute for Medical Research, Cambridge,
United Kingdom)

THE EMBRYONIC ORIGINS OF HEMOPOIETIC STEM CELLS
T. Jaffredo (UPMC, Paris, France)
TRANSCRIPTIONAL CONTROL OF BLOOD STEM CELL DEVELOPMENT
B. Göttgens (School of Clinical Medicine, Cambridge, United Kingdom)
THE ROLE OF POLYCOMB GENES IN PREVENTING HEMOPOIETIC
STEM CELL EXHAUSTION
G. de Haan (University Medical Center, Groningen, The Netherlands)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Mozart I

CHRONIC MYELOID LEUKEMIA - CLINICAL II

Chairs: G. Saglio (University of Turin, Turin, Italy)
P. Rousselot (Hôpital André Mignot, Le Chesney, France)

08:00 - 08:15
0858

COMPARABLE OUTCOME OF MATCHED RELATED AND UNRELATED DONOR STEM CELL TRANSPLANTATION FOR FIRST CHRONIC PHASE CHRONIC MYELOID LEUKEMIA IN THE PROSPECTIVE GERMAN CML III STUDY
M. Hummel, R. Hehlmann, M. Pfirrmann, A. Hochhaus, A. Reiter, H. Heimpel, A. Gratwohl, H.J. Kolb, D.W. Beelen (Universitätsklinikum Mannheim, Mannheim, Germany)

08:15 - 08:30
0859

DASATINIB 140 MG QD VS 70 MG BID IN ADVANCED-PHASE CML OR PH(+) ALL RESISTANT OR INTOLERANT TO IMATINIB: RESULTS FROM A RANDOMIZED, PHASE-III TRIAL (CA180035)
H. Dombret, O. Ottmann, Y. Goh, D.W. Kim, A. Charbonnier, F. Maloisel, C. Bokemeyer, D. Niederwieser, J. Van Tornout, A. Damokosh, J. Cortes (Hopital Saint-Louis, Paris, France)

08:30 - 08:45
0860

NILOTINIB IS ASSOCIATED WITH MINIMAL CROSS INTOLERANCE TO IMATINIB IN PATIENTS WITH IMATINIB-INTOLERANT PHILADELPHIA-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN EITHER CHRONIC PHASE OR ACCELERATED PHASE
G. Rosti, A. Hochhaus, P. Le Coutre, M. Baccarani, K. Bhalla, G. Ossenkoppele, N. Gattermann, A. Haque, A. Weitzman, F. Giles, H. Kantarjian (Institute of Hematology and Oncology, Bologna, Italy)

08:45 - 09:00
0861

IN PATIENTS WITH CHRONIC MYELOGENEOUS LEUKEMIA (CML), RESPONSE DYNAMICS TO NILOTINIB AFTER IMATINIB FAILURE DEPEND ON THE TYPE OF BCR-ABL MUTATIONS
M. Mueller, S. Branford, J. Radich, D.W. Kim, G. Martinelli, G. Saglio, P. Erben, S. Soverini, T. Hughes, Y. Shou, A. Weitzman, M. Baccarani, A. Hochhaus (Med. Fakultaet Mannheim, Uni Heidelberg, Mannheim, Germany)

09:00 - 09:15
0862

COMPARISON OF DASATINIB TO HIGH-DOSE IMATINIB IN PATIENTS WHO EXPERIENCE IMATINIB FAILURE: RESULTS FROM A RANDOMIZED, PHASE-II TRIAL (CA180017, START-R)
G. Martinelli, P. Rousselot, T. Robak, T. Masszi, A. Skotnicki, A. Hellmann, T. Hughes, A. Countouriotis, D. Dejardin, B. Druker (Universita Di Bologna, Bologna, Italy)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Mozart III

NON-HODGKIN'S LYMPHOMA - CLINICAL II

Chairs: A. Hagenbeek (Academic Medical Center, Amsterdam, The Netherlands)
R. Pettengell (St. George’s Hospital, London, United Kingdom)

08:00 - 08:15
0863

PRIMARY EXTRANODAL DIFFUSE LARGE B-CELL LYMPHOMAS (DLBCL) ARISING IN DISTINCT SITES OF HEAD AND NECK HAVE DIFFERENT CLINICAL CHARACTERISTICS AND OUTCOME
S. Cortelazzo, M. Mian, A. Rossi, E. Oldani, M.E. Cabrera, M. Federico, M. Bellei, S. Magrini, M. Buglione, M. Martelli, H. Gomez, A. Lopez-Guillermo, E. Pogliani, F. Rossini, G. Gidano, A. Conconi, M. Busetto, C. Visco, R. Tsang, E. Zucca, A. Rambaldi, F. Cavalli (Hematology BZ, Bolzano, Italy)

08:15 - 08:30
0864

THE CHARACTERISTICS AND CLINICAL COURSE OF MALTLYMPHOMA:
THE UNIVERSITY OF VIENNA EXPERIENCE
M. Raderer, M. Troch, S. Woehrer, B. Streubel, A. Puespoek, K. Turetschek, M. Formanek, U. Jaeger, W. Hauff, J. Drach, A. Chott (University of Vienna, Vienna, Austria)

08:30 - 08:45
0865

IDENTIFICATION OF NEOPLASTIC INFILTRATION OF THE CEREBROSPINAL FLUID (CSF) IN AGGRESSIVE B-NHL:
A MULTICENTER STUDY COMPARING THE UTILITY OF FLOW CYTOMETRY (FCM) VS CONVENTIONAL CYTOLOGY (CC)
S. Quijano (Centro de Investigación del Cáncer, Salamanca, Spain)

08:45 - 09:00
0866

HIGH INCIDENCE OF AUTOIMMUNE COMPLICATIONS IN 82 PATIENTS WITH NON-MALT MARGINAL ZONE LYMPHOMAS
M. Rinaldi, A. Ambrosetti, M. Bonifacio, M. Lestani, O. Perbellini, M.G. Zorzi, A. Bonani, I. Nichele, G. Quaresmini, G. Pizzolo (Poloclinico G.B. Rossi, Verona, Italy)

09:00 - 09:15
0867

COMPREHENSIVE GERIATRIC ASSESSMENT-ADAPTED CHEMOTHERAPY IN 100 ELDERLY PATIENTS (> 70 YEARS) WITH DIFFUSE LARGE B-CELL NON-HODGKIN’S LYMPHOMA (DLBCL)
M. Spina, M. Balzarotti, L. Uziel, A. Ferreri, L. Fratino, A. Giacalone, E. Vaccher, A. Santoro, U. Tirelli (National Cancer Institute, Aviano (pn), Italy)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Strauss I

ACUTE MYELOID LEUKEMIA - BIOLOGY I

Chairs: A. Biondi (University of Milano-Bicocca, Milan, Italy)
H. Döhner (University of Ulm, Ulm, Germany)

08:00 - 08:15
0868

LESTAURTINIB INDUCES INCREASED CYTOTOXICITY IN PRIMARY AML BLASTS WITH A FLT3 INTERNAL TANDEM DUPLICATION COMPARED TO THOSE WITH WILD TYPE OR TYROSINE KINASE DOMAIN MUTATED FLT3
A. Mead, A. Khwaja, P. Kottaridis, D. Linch, R. Gale (UCL, London, United Kingdom)

08:15 - 08:30
0869

HIGH RESOLUTION SNP ARRAYS AND MIRNA GENE EXPRESSION REVEALS PREVIOUSLY UNIDENTIFIED ABERRATIONS IN PATIENTS WITH AML AND NORMAL KARYOTYPE
C. Vicente, I. Vazquez, E. Bandres, N. Marcotegui, G. Rivell, I. Cristobal, C. Carranza, M.J. Larrayoz, I. Lahortiga, M.J. Calasanz, M.D. Odero (Center for Applied Medical Research, Pamplona, Spain)

08:30 - 08:45
0870

SEGMENTAL UNIPARENTAL DISOMY IS THE MOST COMMONLY ACQUIRED GENETIC ABNORMALITY IN RELAPSED ACUTE MYELOID LEUKEMIA
M. Raghavan (Barts & the London School of Medicine, London, United Kingdom)

08:45 - 09:00
0871

DERIVATION OF A GLOBAL MAP OF DNA HOMOZYGOSITY IN ACUTE MYELOID LEUKEMIA (AML)
M. Gupta (Barts and The London, London, United Kingdom)

09:00 - 09:15
0872

MN1 INDUCES LEUKEMIA IN MICE AND PREDICTS ATRA RESISTANCE AND SENSITIVITY IN AML PATIENTS
M.H. Heuser, B. Argiropoulos, F. Kuchenbauer, E. Yung, J. Piper, S. Fung, R.F. Schlenk, K. Dohner, T. Hinrichsen, C. Rudolph, A. Schambach, C. Baum, B. Schlegelberger, H. Dohner, A. Ganser, R.K. Humphries (British Columbia Cancer Agency, Vancouver, Canada)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Strauss II

ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY

Chairs: D. Hoelzer (University of Frankfurt, Frankfurt, Germany)
S. Izraeli (Sheba Medical Center, Ramat Gan, Israel)

08:00 - 08:15
0873

DIFFERENTIAL CHROMOSOMAL BREAKPOINTS IMPACT LEVEL OF LMO2 EXPRESSION IN T-ALL
A.W. Langerak, W.A. Dik, B. Nadel, G.K. Przybylski, V. Asnafi, P. Grabarczyk, J.M. Navarro, B. Verhaaf, C.A. Schmidt, E.A. Macintyre, J.J.M. Van Dongen (Erasmus MC, Rotterdam, The Netherlands)

08:15 - 08:30
0874

EVIDENCE FOR POSTNATAL ORIGIN OF CHILDHOOD T-LINEAGE ALL
R. Panzer-Grümayer, S. Fischer, G. Mann, M. Metzler, G. Ebetsberger, N. Jones, B. Nadel, O. Bodamer, O.A. Haas, K. Schmitt, H. Gadner (Children's Cancer Research Institute, Vienna, Austria)

08:30 - 08:45
0875

EML1-ABL1 IS ACTIVATED BY COILED COIL MEDIATED OLIGOMERIZATION AND INDUCES T-CELL ACUTE LYMPHOBLASTIC OR CHRONIC MYELOID LEUKEMIA IN A MOUSE BONE MARROW TRANSPLANT MODEL
K. De Keersmaecker, H. Verachtert, W. Landuyt, C. De Wolf-Peeters, P. Vandenberghe, J. Schwaller, P. Marynen, J. Cools (University of Leuven, Leuven, Belgium)

08:45 - 09:00
0876

ANALYSIS OF PAIRED PRESENTATION AND RELAPSE SAMPLES IN T-ALL SUGGESTS THAT, AT LEAST IN SOME PATIENTS, NOTCH- 1 MUTATIONS MAY BE ACQUIRED AS A SECONDARY EVENT
M. Mansour, V. Duke, B. Patel, P. Ancliff, L. Foroni, R.E. Gale, D.C. Linch (University College London, London, United Kingdom)

09:00 - 09:15
0877

PAX5/TEL TRANSDUCED PRE-BI CELLS ARE RESISTANT TO TGF-BETA1 AND MIGRATE TOWARDS SDF-1ALPHA
G. F. Fazio, C. Palmi, V. Andrè, A Biondi, A. Rolink, G. Cazzaniga (Tettamanti Reserach Center, Monza, Italy)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Strauss III

THROMBOSIS AND BLEEDING DISORDERS

Chairs: R. Bertina (University Medical Center, Leiden, The Netherlands)
P. Mannucci (A. Bianchi Bonomi Center, Milan, Italy)

08:00 - 08:15
0878

SOLUBLE P-SELECTIN AND THROMBOSIS RISK OF PATIENTS WITH A PERSISTENT LUPUS ANTICOAGULANT IN A PROSPECTIVE COHORT STUDY
R. Vormittag, S. Panzer, C. Ay, P. Quehenberger, S. Koder, I. Pabinger (MUW, Vienna, Austria)

08:15 - 08:30
0879

P-SELECTIN GENE HAPLOTYPES MODULATE SOLUBLE PSELECTIN LEVELS AND CONTRIBUTE TO THE RISK OF VENOUS THROMBOEMBOLISM
C. Ay, L.V. Jungbauer, A. Kaider, S. Koder, S. Panzer, I. Pabinger, M. Mannhalter (Medical University Vienna, Vienna, Austria)

08:30 - 08:45
0880

A HIGH PLATELET COUNT INDEPENDENTLY PREDICTS VENOUS THROMBOEMBOLISM IN CANCER PATIENTS – RESULTS FROM THE VIENNA CANCER AND THROMBOSIS STUDY (CATS)
R. Simanek, R. Vormittag, G. Alguel, C. Ay, D. Dunkler, P. Quehenberger, C. Zielinski, U. Jäger, I. Pabinger (Medical University of Vienna, Vienna, Austria)

08:45 - 09:00
0881

INCIDENCE AND DETERMINANTS OF BLEEDING IN VON WILLEBRAND DISEASE: RESULTS OF THE FIRST PROSPECTIVE MULTICENTER STUDY ON 814 ITALIAN PATIENTS
A.B. Federici, P. Bucciarelli, G. Castaman, M.G. Mazzucconi, M. Morfini, A. Rocino, M. Schiavoni, F. Rodeghiero, P.M. Mannucci (University of Milan, Milan, Italy)

09:00 - 09:15
882

CISPLATIN INDUCES THROMBIN GENERATION VIA FORMATION OF PROCOAGULANT ENDOTHELIAL MICROPARTICLES IN VITRO
D. Lechner, M. Kollars, A. Gleiss, S. Eichinger, P.A. Kyrle, A. Weltermann (Medical University of Vienna, Vienna, Austria)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Léhar III+IV

MYELOMA / MGUS / WM - BIOLOGY

Chairs: J. Drach (Medical University, Vienna, Austria)
G. Morgan (Royal Marsden Hospital, London, United Kingdom)

08:00 - 08:15
0883

IMPACT OF CONSOLIDATION WITH BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE ON RESIDUAL MULTIPLE MYELOMA CELLS AFTER AUTOLOGOUS TRANSPLANTATION ASSESSED BY QUALITATIVE AND QUANTITATIVE PCR
M. Ladetto, M. Astolfi, L. Santo, I. Avonto, F. Cavallo, G. Pagliano, P. Pregno, M. Grasso, A.M. Liberati, T. Caravita, F. Pisani, T. Guglielmelli, E. Genuardi, R. Crivelli, C. Cristiano, D. Drandi, M. Boccadoro, A. Palumbo (Università di Torino, Turin, Italy)

08:15 - 08:30
0884

THE PROTEASOME INHIBITOR BORTEZOMIB STIMULATES THE OSTEOGENIC DIFFERENTIATION OF HUMAN MYSENCHYMAL CELLS IN VITRO AND MAY RESTORE THE NUMBER OF OSTEOBLASTIC CELLS IN MULTIPLE MYELOMA PATIENTS
N. Giuliani, S. Tagliaferri, M. Lazzaretti, F. Morandi, M. Crugnola, S. Bonomini, C. Mancini, E. Martella, C. Colla, G. Sammarelli, V. Rizzoli (Hematology, Parma, Italy)

08:30 - 08:45
0885

ANGIOPOIETIN1/ANGIOPOIETIN2 RATIO IS REDUCED AND CORRELATES WITH DISEASE SEVERITY IN RELAPSED/REFRACTORY MYELOMA PATIENTS. NORMALIZATION OF THE RATIO POST BORTEZOMIB THERAPY
K. Anargyrou, E. Terpos, S. Sachanas, T. Tzenou, S. Masouridis, T. Christoulas, M.K. Angelopoulou, S.I. Kokoris, T.P. Vassilakopoulos, M.P. Siakantaris, C. Kalpadakis, P. Panayiotidis, K. Tsionos, G.A. Pangalis, M.C. Kyrtsonis (251 General Air force Hospital, Athens, Greece)

08:45 - 09:00
0886

STABLE ASYMPTOMATIC MYELOMA AND MGUS IN THE PRESENCE OF T(4;14)
M. Ross, L. Chiecchio, R.K.M. Protheroe, G.P. Dagrada, D.M. Stockley, M. Nightingale, N.C.P. Cross, C.J. Harrison, K.H. Orchard (University of Southampton, Salisbury, United Kingdom)

09:00 - 09:15
0887

DELETIONS OF CHROMOSOMES 6Q AND 13Q, AND TRISOMY 4 ARE THE MOST COMMON CYTOGENETIC ABNORMALITIES IN WALDENSTRÖM MACROGLOBULINEMIA. PRELIMINARY RESULTS OF A MULTICENTRIC STUDY
F. Nguyen-Khac, E. Chapiro, C. Barin, N. Gachard, A. Daudignon, C. Terre, V. Eclache, I. Luquet, V. Soenen, C. Henry, H. Mossafa, S. Ramond, B. Perissel, C. Bastard, S. Struski, C. Bilhou-nabera, M.-J. Gregoire, E. Callet-Bachu, M.-J. Mozziconacci, F. Mugneret, H. Merle-beral, V. Leblond (Hopital Pitie-Salpetriere, Paris, France)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Stolz I

GENOMICS AND PROTEOMICS

Chairs: J. Cools (University of Leuven-VIB, Leuven, Belgium)
O. Hantschel (Austrian Academy of Science, Vienna, Austria)

08:00 - 08:15
0888

PHOSPHOPROTEOMIC PROFILING OF PEDIATRIC B-ALL PATIENTS USING REVERSE PHASE PROTEIN ARRAYS
B. Accordi, V. Espina, G. Te Kronnie, L. Liotta, E. Petricoin, III, G. Basso (University of Padua, Padova, Italy)

08:15 - 08:30
0889

MRNA EXPRESSION PROFILING IN ADULT ACUTE MYELOID LEUKEMIA IDENTIFIES DISTINCT SUBCLASSES
L. Bullinger, S. Sander, K. Holzmann, A. Russ, H. Kestler, J.R. Pollack, R.F. Schlenk, K. Dohner, H. Dohner (University of Ulm, Ulm, Germany)

08:30 - 08:45
0890 IDENTIFICATION OF CANDIDATE GENES IN HIGH-LEVEL DNA AMPLIFICATIONS IN AML WITH COMPLEX KARYOTYPE USING AN ARRAY-BASED APPROACH
F. Rucker, L. Bullinger, S. Miller, H. Kestler, P. Lichter, K. Dohner, H. Dohner (University of Ulm, Ulm, Germany)

08:45 - 09:00
0891

AN INTERNATIONAL MULTI-CENTER RESEARCH STUDY TO DEFINE THE APPLICATION OF MICROARRAYS IN THE DIAGNOSIS AND SUBCLASSIFICATION OF LEUKEMIA (MILE STUDY):
A REPORT ON 2926 CASES
T. Haferlach, A. Kohlmann, K. Mills, W.K. Hofmann, T. te Kronnie, G. Basso, J. Hernandez Rivas, J. Downing, A. Yeoh, J. De Vos, M.C. Béné, C. Preudhomme, E. Macintyre, T. Kipps, L. Wieczorek, R. Foa (MLL, Munich Leukemia Laboratory, Munich, Germany)

09:00 - 09:15
0892

INTEGRATION OF GENOME WIDE SNP ARRAYS AND GENE EXPRESSION DATA OF CHILDHOOD ALL WITHOUT KNOWN GENETIC ABERRATIONS IDENTIFY SUBGROUPS WITH SPECIFIC GENETIC HALLMARKS
S. Bungaro, M. Campo dell’Orto, D. Basso, A. Zangrando, T.A. Gorletta, M. Raghavan, A. Leszl, B.D. Young, G. Basso, S. Bicciato, G. Te Kronnie, A. Biondi, G. Cazzaniga (M.Tettamanti Research Center, Monza, Italy)

HEMATOLOGY-IN-FOCUS SESSION

09.30 - 10.15 hours, Room: Mozart I

CLINICAL IMPLICATIONS OF FLT3 IN ACUTE MYELOID LEUKEMIA

Chair: F. Lo Coco (University Tor Vergata, Rome, Italy)

MUTATIONS AS PROGNOSTIC AND PREDICTIVE FACTORS IN AML
K. Döhner (University Hospital of Ulm, Ulm, Germany)
PRE-CLINICAL AND CLINICAL IMPACT OF FLT3 INHIBITORS
A. Burnett (University of Wales, College of Medicine, Cardiff, United Kingdom)

HEMATOLOGY-IN-FOCUS SESSION

09.30 - 10.15 hours, Room: Mozart II

DEVELOPMENT OF NEW MONOCLONAL ANTIBODIES IN NHL

Chair: G. Salles (Centre Hospitalier Lyon-Sud, Lyon, France)

PHARMACOGENETICS OF THERAPEUTIC ANTIBODIES: IMPLICATION OF FCGR3A POLYMORPHISM
V. Suraud (Université Francois-Rabelais de Tours, Tours, France)
WHAT HAVE WE LEARNT FROM CLINICAL TRIALS OF MONOCLONAL ANTIBODIES IN LYMPHOMA?
A. Hagenbeek (Academic Medical Center, Amsterdam, The Netherlands)

HEMATOLOGY-IN-FOCUS SESSION

09.30 - 10.15 hours, Room: Mozart III

ZAP-70 IN CHRONIC LYMPHOCYTIC LEUKEMIA

Chair: H. Döhner (University Hospital, Internal Med.III, Ulm, Germany)

ZAP-70 IN B-CELL RECEPTOR SIGNALLING
T. Kipps (University of California, San Diego, USA)
IS THERE A ROLE OF ZAP-70 FOR GUIDING TREATMENT DECISIONS?
F. Bosch (Hospital Clinic, Barcelona, Spain)

HEMATOLOGY-IN-FOCUS SESSION

09.30 - 10.15 hours, Room: Strauss I

HOT TOPICS IN TRANSFUSION MEDICINE

Chair: B. Mansouri (University Hospital, Inselspital, Bern, Switzerland)

NON-INVASIVE PRENATAL DIAGNOSIS OF FETAL RHESUS D
C. van der Schoot (Sanquin, Amsterdam, The Netherlands)
THE BLOODGEN PROJECT: TOWARDS MASS SCALE COMPREHENSIVE GENOTYPING OF BLOOD DONORS IN THE EUROPEAN UNION AND BEYOND
N. Avent (Bristol Genomics Research Institute, Bristol, United Kingdom)

HEMATOLOGY-IN-FOCUS SESSION

09.30 - 10.15 hours, Room: Strauss II

THROMBOTIC THROMBOCYTOPENIC PURPURA

Chair: B. Lämmle (Klinik und Poliklinik fur Hämatologie, Bern, Switzerland)

THE REGULATION OF ADAMTS 13-VWF INTERACTION
R. De Cristofaro (Catholic University School of Medicine, Rome, Italy)
MANAGEMENT OF TTP
S. Machin (University College London, London, United Kingdom)

HEMATOLOGY-IN-FOCUS SESSION

09.30 - 10.15 hours, Room: Strauss III

CONGENITAL NEUTROPENIAS

Chair: N. Borregaard (University of Copenhagen, Rigshospitalet, Copenhagen, Denmark)

GENETIC CONTROL OF NEUTROPHIL PRODUCTION: NEW INSIGHT INTO SEVERE CONGENITAL NEUTROPENIA
K. Welte (Medical School Hanover, Hanover, Germany)
MOLECULAR BASIS OF SHWACHMAN-DIAMOND SYNDROME
C. Wong (University of Cambridge, Cambridge, United Kingdom)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Mozart I

MYELOPROLIFERATIVE DISORDERS - CLINICAL

Chairs: T. Barbui (Ospedali Riuniti, Bergamo, Italy)
A. Reiter (University of Heidelberg, Heidelberg, Germany)

10:30 - 10:45
0893

HIGH TROUGHPUT SEQUENOM BASED ASSAY FOR MONITORING JAK2 V617F POST ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO SCT) FOR CLASSIC MYELOPROLIFERATIVE DISORDERS (MPD)
M. Koren-Michowitz, Y. Cohen, A. Shimoni, N. Amariglio, A. Nagler (Chaim Sheba Medical Center, Ramat Gan, Israel)

10:45 - 11:00
0894

JAK2 EXON 12 MUTATIONS OCCUR FREQUENTLY IN IDIOPATHIC ERYTHROCYTOSIS PATIENTS WITH LOW SERUM ERYTHROPOIETIN LEVELS
M.J. Percy, L.M. Scott, W.N. Erber, C.N. Harrison, J.T. Reilly, F.G.C. Jones, A.R. Green, M.F. McMullin (Belfast City Hospital, Belfast, United Kingdom)

11:00 - 11:15
0895

THE IMPACT OF V617F JAK-2 GENE MUTATION ON PLATELET, GRANULOCYTE AND PLASMA HEMOSTATIC AND INFLAMMATORY MOLECULES IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
A. Falanga, M. Marchetti, A. Vignoli, D. Balducci, L. Russo, V. Guerini, T. Barbui (Ospedali Riuniti di Bergamo, Bergamo, Italy)

11:15 - 11:30
0896

HIGHER LEUKOCYTE COUNT IS A RISK FACTOR FOR THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA
E. Antonioli, P. Guglielmelli, A. Tosetto, G. Poli, M. Bernardi, V. Ponziani, F. Rodeghiero, A. Bosi, M. Ruggeri, A.M. Vannucchi (University of Florence, Florence, Italy)

11:30 - 11:45
0897

THE PHENOTYPE OF JAK2V617F MUTANT PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA IS NOT RELATED TO THE BURDEN OF MUTANT ALLELE
E. Antonioli, P. Guglielmelli, G. Poli, G. Longo, V. Ponziani, A. Pancrazzi, A. Bosi, A.M. Vannucchi (University of Florence, Florence, Italy)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Mozart III

ACUTE MYELOID LEUKEMIA - BIOLOGY II

Chairs: F. Lo Coco (University Tor Vergata, Rome, Italy)
M. Alberich Jorda (Harvard Institute of Medicine, Boston, USA)

10:30 - 10:45
0898

UNRAVELING LEUKAEMOGENIC MECHANISMS AND TARGETS OF NUP98/HOMEO-DOMAIN RECOMBINATIONS IN AML THROUGH A NEW NUP98/HHEX FUSION GENE
J. Schwaller, D. Jankovic, P. Gorello, R. La Starza, C. Desjobert, T. Liu, S. Ehret, P.-S. Jayaraman, C. Mecucci (University Hospital Basel, Basel, Switzerland)

10:45 - 11:00
0899

THE ALTERNATIVELY SPLICED ISOFORM AML1-ETO9A IS DETECTABLE IN ALL T(8;21)-POSITIVE ACUTE MYELOID LEUKEMIAS: CORRELATION OF THE EXPRESSION LEVEL WITH CLINICAL OUTCOME
Ch. Schön, R.F. Schlenk, J. Vehma, K. Eiwen, H. Döhner, K. Döhner (Uniklinikum Ulm, Ulm, Germany)

11:00 - 11:15
0900

CRYPTIC 3Q26 ABERRATIONS PARTLY EXPLAIN ABNORMAL EXPRESSION OF EVI1 IN AML CASES WITHOUT CYTOGENETICALLY RECOGNIZABLE TRANSLOCATIONS IN THIS LOCUS
L. Sanne, E. Van Drunen, H. Beverloo, Y. Van Norden, P.J.M. Valk, B. Lowenberg, H.R. Delwel (Erasmus MC, Rotterdam, The Netherlands)

11:15 - 11:30
0901

THE T(6;9) ASSOCIATED DEK/CAN FUSION PROTEIN DOES NOT BLOCK DIFFERENTIATION OF EARLY HEMATOPOIETIC STEM CELLS BUT INCREASES THEIR SELF RENEWAL POTENTIAL
M. Ruthardt, C. Oancea (Klinikum der J. W. Goethe Universität, Frankfurt, Germany)

11:30 - 11:45
0902

BORN TO BE EXPORTED: C-TERMINUS NUCLEAR EXPORT SIGNALS OF DIFFERENT STRENGTH ENSURE CYTOPLASMIC ACCUMULATION OF NUCLEOPHOSMIN LEUKEMIC MUTANTS
N. Bolli, I. Nicoletti, M.F. De Marco, B. Bigerna, A. Pucciarini, R. Mannucci, M.P. Martelli, B.R. Henderson, B. Falini (Institute of Hematology, Perugia, Italy)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Strauss I

CHRONIC MYELOID LEUKEMIA - BIOLOGY

Chairs: T. Hughes (Royal Adelaide Hospital, Adelaide, Australia)
J. Melo (Imperial College, London, United Kingdom)

10:30 - 10:45
0903

BMS-214662 TARGETS AN EARLY PROGENITOR POPULATION IN PRIMARY CML AND INDUCES APOPTOSIS IN THE QUIESCENT FRACTION AFTER SENSITIZATION BY THE MEK 1/2 INHIBITOR U0126
F. Pellicano, M. Copland, H. Jorgensen, T. Holyoake (University of Glasgow, Glasgow, United Kingdom)

10:45 - 11:00
0904

THE P-LOOP MUTATIONS Y253H AND E255K/V MAY DEVELOP MORE FREQUENTLY THAN T315I DURING NILOTINIB THERAPY AFTER IMATINIB FAILURE AND ARE ASSOCIATED WITH PROGRESSION IN PATIENTS WITH PH-POSITIVE LEUKEMIA
S. Branford, Y. Shou, R. Lawrence, Z. Rudzki, T. Hughes (Institute of Medical &Veterinary Science, Adelaide, Australia)

11:00 - 11:15
0905

NOVEL PATHWAY IN BCR-ABL SIGNAL TRANSDUCTION INVOLVES AKT-INDEPENDENT ACTIVATION OF PLC-GAMMA/MTOR/P70-S6 KINASE
B. Markova, F. Breitenbuecher, J.V. Melo, J. Duyster, C. Huber, T. Fischer (University Hospital, Mainz, Germany)

11:15 - 11:30
0906

DELETIONS OF THE DERIVATIVE CHROMOSOME 9 DO NOT INFLUENCE RESPONSE TO IMATINIB IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS (A GIMEMA WORKING PARTY ANALYSIS)
F. Castagnetti, F. Palandri, G Marzocchi, S. Luatti, N. Testoni, M. Amabile, S. Soverini, S. Kerim, E. Giugliano, G. Specchia, A. Cuneo, G. Martinelli, G. Alimena, M. Baccarani, G Rosti (Institute of Hematology "Seràgnoli", Bologna, Italy)

11:30 - 11:45
0907

THE INTRACELLULAR CONCENTRATIONS OF IMATINIB AND NILOTINIB, CAN BE SUBSTANTIALLY ALTERED BY INTERACTION WITH OTHER DRUGS: STUDIES WITH PROTON PUMP INHIBITORS
D. White, V.A. Saunders, P. Dang, K. Lynch, P. Manley, T.P. Hughes (IMVS and Hanson Institute, Adelaide, Australia)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Strauss II

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY

Chairs: M. Ferrarini (National Institute for Cancer Research, Genoa, Italy)
S. Stilgenbauer (University of Ulm, Ulm, Germany)

10:30 - 10:45
0908

EXPRESSION LEVELS OF CLLU1 AND LPL : NEW DISEASEASSESSMENT TOOLS IN CLL PATIENTS IN BINET STAGE A ?
S. Hayette, S. Hayette, C. Bastard, M.J. Mozziconacci, C. Messana, C. Charlot, C. Locher, M. Gadoux, L. Baseggio, M. Ticchioni, B. Lenormand, G. Salles, C. Arnoulet, J.P. Magaud, E. Callet-Bauchu, S. Raynaud (Centre Hospitalier Lyon Sud, Pierre-Benite, France)

10:45 - 11:00
0909

QUANTITATIVE GENE EXPRESSION ANALYSIS OF SURROGATE MARKERS FOR GENETIC RISK GROUPS AND SURVIVAL IN CLL
D.K. Kienle, A. Benner, C.S. Schneider, D.W. Winkler, A.H. Habermann, M.H. Hensel, P. Lichter, R.D. Dalla-Favera, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany)

11:00 - 11:15
0910

FUNCTIONAL IMPAIRMENT OF THE P53 PATHWAY DETECTED BY FLOW CYTOMETRY IS A NOVEL INDEPENDENT ADVERSE PROGNOSTIC FACTOR IN CHRONIC LYMPHOCYTIC LEUKAEMIA
A.R. Pettitt, A Carter, K. Lenehan, K. Lin (University of Liverpool, Liverpool, United Kingdom)

11:15 - 11:30
0911

THE ANTITUMOR ACTIVITY OF LUMILIXIMAB IS MEDIATED THROUGH THE INDUCTION OF CASPASE-9–DEPENDENT APOPTOSIS AND IS SYNERGISTIC WITH RITUXIMAB AND FLUDARABINE IN CD23+ CLL AND LYMPHOMA CELLS
N. Pathan, J.C. Byrd, K. Hariharan, P. Chu, A. Molina (Biogen Idec, San Diego, USA)

11:30 - 11:45
0912

IN VITRO MODEL FOR LYMPHOID MICROENVIRONMENT AND INHIBITION OF APOPTOSIS IN B-CLL CELLS: INVOLVEMENT OF PI3-K/AKT PATHWAY AND PTEN
M. Shehata, S. Schnabl, D. Demirtas, J.D. Schwarzmeier, M. Hilgarth, M. Duechler, A. Gaiger, R. Hubmann, U. Jaeger (Medical University of Vienna, Vienna, Austria)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Strauss III

RED CELLS AND IRON

Chairs: P. Beris (Geneva University Hospital, Geneva, Switzerland)
W. van Solinge (University Medical Center Utrecht, Utrecht, The Netherlands)

10:30 - 10:45
0913

PLASMA LIPOCALIN-2 LEVELS IN PATIENTS WITH THALASSEMIA INTERMEDIA: CORRELATION WITH IRON METABOLISM AND ERYTHROPOIESIS
I. Papassotiriou, A. Margeli, V. Ladis, S. Sophia, K. Kassiou, A. Kattamis (Aghia Sophia Children's Hospital, Athens, Greece)

10:45 - 11:00
0914

ZOLEDRONIC ACID INCREASES BONE MINERAL DENSITY IN PATIENTS WITH THALASSEMIA INTERMEDIA-INDUCED OSTEOPOROSIS DESPITE THE CONTINUOUS BONE MARROW EXPANSION
E. Voskaridou, D. Christoulas, L. Antoniadou, P. Tsaftaridis, E. Plata, E. Terpos (Thalassemia Center, Laikon General Hosp., Athens, Greece)

11:00 - 11:15
0915

PROTEOMIC AND BIOCHEMICAL PROFILING OF 4.1R DEFICIENT RED BLOOD CELLS
K. Jeremy, Z. Plummer, D. Head, J. Delaunay, N. Avent (University of the West of England, Bristol, United Kingdom)

11:15 - 11:30
0916

INHIBITION OF INCREASED SICKLE NEUTROPHIL ADHESION TO ICAM-1 BY NITRIC OXIDE DONORS AND ACTIVATION OF CGMP SIGNALING
A. Canalli, N. Conran, S.T.O. Saad, F.F. Costa (Unicamp, Campinas, Brazil)

11:30 - 11:45
0917

USEFULNESS OF THE EOSIN-5’-MALEIMIDE CYTOMETRIC METHOD AS A FIRST-LINE SCREENING TEST FOR THE DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS: COMPARISON WITH EKTACYTOMETRY AND PROTEIN ELECTROPHORESIS
F. Girodon, L. Garçon, M. Largier, E. Bergoin, J. Delaunay, M. Thibaut, M. Maynadié, T. Cynober (CHU Bocage, Dijon, France)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Léhar I+II

NON-HODGKIN'S LYMPHOMA - BIOLOGY

Chairs: A. Rosenwald (University of Würzburg, Würzburg, Germany)
G. Salles (Centre Hospitaire Lyon-Sud, Lyon, France)

10:30 - 10:45
0918

JUNCTIONAL ADHESION MOLECULE C (JAM-C) DIFFERENTIATES CD27 POSITIVE B LYMPHOCYTES INTO GERMINAL CENTER AND NON-GERMINAL CENTER CELLS AND CONSTITUTES A NEW DIAGNOSTIC MARKER FOR B CELL MALIGNANCIES
Th. Matthes, C. Ody, S. Jungblut-Ruault, D. Cossali, M. Barnet, M. Aurrand-Lions, B. Imhof (University Hospital Geneva, Geneva, Switzerland)

10:45 - 11:00

0919

ROLE OF JUNB IN ALCL LYMPHOMA DEVELOPMENT
D. Laimer, P. Vesely, P. Staber, P. Pflegerl, R. Brandes, M. Schlederer, G. Hoefler, L. Kenner (Medical University Vienna, Vienna, Austria)

11:00 - 11:15
0920

THE ONCOPROTEIN NPM-ALK INDUCES TRANSLATION OF AP-1 FACTORS VIA MTOR SIGNALLING
P. Staber, P. Vesely, C. Fuchs, I. Bambach, S. Schauer, H. Bergler, D. Sternberg, G. Hoefler (Medical University Graz, Graz, Austria)

11:15 - 11:30
0921

ANALYSIS OF MICRORNAS EXPRESSION PATTERN IN CLASSICAL HODGKIN LYMPHOMA
A. Navarro, A. Gaya, A. Urbano-Ispizua, A. Pons, A. Martinez, B. Gel, O. Balague, P. Abrisqueta, A. Lopez-Guillermo, R. Artells, E. Montserrat, M. Monzo (University of Barcelona, Barcelona, Spain)

11:30 - 11:45
0922

FREQUENT CRYPTIC ALTERATIONS DETECTED BY SNP-CHIPS IN BURKITT LYMPHOMAS
V. Havelange, E. Callet-Bauchu, I. Theate, F. Mugneret, L. Michaux, C. Barin, N. Dastugue, E. Lippert, P. Saussoy, D. Penther, M. Vikkula, H. Poirel (Cliniques Universitaires Saint-Luc, Brussels, Belgium)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Léhar III+IV

CYTOGENETICS, MOLECULAR DIAGNOSTICS AND TARGETED THERAPIES

Chairs: B. Schlegelberger (Hanover Medical School, Hanover, Germany)
C. Chomienne (Institute Universitaire d’Hematologie, Paris, France)

10:30 - 10:45
0923

HIGH RESPONSE RATE AFTER SEQUENTIAL ADMINISTRATION OF AZACITIDINE, VALPROIC ACID, AND ATRA IN PREVIOUSLY UNTREATED OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
E. Raffoux, C. Recher, N. Boissel, R. Oumedaly, I. Lobe, F. Huguet, D. Rea, P. Chaibi, A. De Labarthe, P. Fenaux, L. Degos, C. Gardin, H. Dombret (Hopital Saint Louis, Paris, France)

10:45 - 11:00
0924

TARGETING ICMT AMELIORATES K-RAS-INDUCED MYELOPROLIFERATIVE DISEASE AND LUNG CANCER
M. Bergo, A.M. Wahlstrom, M. Liu, C. Karlsson, B. Swolin, B.A. Cutts (Sahlgrenska University Hospital, Goteborg, Sweden)

11:00 - 11:15
0925

PROGNOSTIC IMPACT OF CHROMOSOMAL ABNORMALITIES IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA TREATED WITH HIGH-DOSE MELPHALAN (MEL140) AND AUTOLOGOUS STEM CELL TRANSPLANTATION
P. Liebisch, C. Straka, A. Wimmer, C. Wendl, A. Hinke, S. Ibach, H. Döhner (University Hospital of Ulm, Ulm, Germany)

11:15 - 11:30
0926

A NEW APPROACH TO MRD MONITORING IN AML, REAL-TIME QUANTIFICATION OF MULTIPLE AML-UPREGULATED GENES
K. Tobal, G.J. Mufti (King's College Hospital, London, United Kingdom)

11:30 - 11:45
0927

MK-0457, A NOVEL MULTIKINASE INHIBITOR, IS ACTIVE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AND ACUTE LYMPHOCYTIC LEUKEMIA (ALL) WITH THE T315I BCRABL RESISTANCE MUTATION AND PATIENTS WITH REFRACTORY JAK-2 POSITIVE MYELOPROLIFERATIVE DISEASES (MPD)
J. Giles, J. Cortes, D.A. Bergstrom, A. Xiao, D. Jones, S. Verstovsek, D. Thomas, D. Rizzieri, S.J. Freedman, H. Kantarjian (M.D. Anderson Cancer Center, Houston, USA)

SIMULTANEOUS SESSION

10:30 - 11:45 hours, Room: Stolz I

EPIGENETICS, TRANSCRIPTION AND SIGNALLING

Chairs: G. de Haan (University Medical Center, Groningen, The Netherlands)
K. Podar (Dana-Farber Cancer Institute, Boston, USA)

10:30 - 10:45
0928

TRANSCRIPTIONAL REGULATION OF HEMO-OXIGANASE-1 AND A SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE (SPARC) IN BORTEZOMIB-TREATED ADULT T-CELL LEUKEMIA CELLS
H. Ryoko, J.H. Ohyashiki, C. Kobayashi, A. Hirota, Y. Zhang, T. Takaku, K. Ohyashiki (Tokyo Medical University, Tokyo, Japan)

10:45 - 11:00
0929

LACK OF MHC-II MOLECULE EXPRESSION IN T-LEUKAEMIA IS ASSOCIATED WITH DISTINCT EPIGENETIC DNA AND HISTONE MODIFICATIONS AT PROMOTER III CHROMATIN OF MHC2TA
P.J. van den Elsen, T.M. Holling, M.C.J.A. Van Eggermond (Leiden University Medical Center, Leiden, The Netherlands)

11:00 - 11:15
0930

UNCOVERING THE EPIGENETIC PATHOMECHANISM IN 13Q14
D. Mertens, M. Ruppel, A. Philippen, C. Tschuch, V. Fleig, C. Mund, F. Lyko, B. Radlwimmer, H. Döhner, S. Stilgenbauer, P. Lichter (University Hospital Ulm, DKFZ Heidelberg, Ulm, Germany)

11:15 - 11:30
0931

BETA-TRCP MEDIATES UBIQUITINATION AND DEGRADATION OF THE ERYTHROPOIETIN RECEPTOR AND CONTROLS CELL PROLIFERATION
F. Verdier, L. Meyer, B. Deau, H. Forejtnikova, D. Dumenil, F. Margottin-Goguet, C. Lacombe, P. Mayeux (Cochin Institute, Paris, France)

11:30 - 11:45
0932

IDENTIFICATION OF PROTEIN TYROSINE KINASES THAT CAN SUPPORT THE PROLIFERATION AND SURVIVAL OF HEMATOPOIETIC CELLS
E. Lierman (K.U. Leuven, Leuven, Belgium)

CLINICAL TRIAL UPDATE

10.30-11.45 hours, Room: Mozart II

MULTIPLE MYELOMA

Chair: J. San Miguel (Hospital Universitario de Salamanca, Salamanca, Spain)

FRENCH GROUP (IFM)
J. Harousseau (Hôtel Dieu, Nantes, France)
ITALIAN GROUP
M. Boccadoro (Università di Torino, Turin, Italy)
U.K (MRC)
G. Morgan (Royal Marsden Hospital, London, United Kingdom)
DUTCH/GERMAN (HOVON/ GMSG)
P. Sonneveld (Erasmus Medical Center, Rotterdam, The Netherlands)
SPANISH (GEM-PETHEMA)
M. Mateos (University of Salamanca, Salamanca, Spain)

[ Top of page ]